Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative
Abstract:Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.
Document Type: Short Communication
Affiliations: 1: Stop TB Department, World Health Organization, Geneva, Switzerland 2: Socios En Salud, Lima, Peru 3: State Centre of Tuberculosis and Lung Diseases of Latvia, Riga, Latvia 4: MDR-TB Project in Tomsk Oblast, Partners in Health/Harvard Medical School, Tomsk, Russian Federation 5: Tropical Disease Foundation, Makati Medical Center, Manila, Philippines 6: Lung Clinic, Tartu University Clinics, Tartu, Estonia
Publication date: November 1, 2004
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites